Laguna Diagnostics, llc.

Blood-based

Molecular

Biomarker

Diagnostic Tests

 

Laguna Diagnostics, LLC, develops proprietary blood-based, molecular biomarker diagnostic tests for accurate diagnosis of mental disorders and neurodegenerative diseases.

 

First Products are blood-based, gene expression tests to diagnose and differentiate schizophrenia and bipolar disorder from control subjects. Published study, "Exon Array Biomarkers for the Differential Diagnosis of Schizophrenia and Bipolar Disorder" appears in Molecular Neuropsychiatry 2017; 3: 197–213, 2018 issue. The abstract is available online at www.karger.com/Article/Abstract/485800.

 

Press Release: Laguna Diagnostics Announces Publication of Peer-Reviewed Study in Molecular Neuropsychiatry. (read)

 

Schizophrenia and Bipolar Disorder

Schizophrenia (SZ), bipolar I disorder (BD) are chronic, severe, and disabling brain disorders affecting approximately 1 and 2%, respectively, of the US population 18 years and older. One estimate of the direct and indirect annual costs in the US for SZ is $174 billion and an additional $151 billion for BD. Today, diagnosis and treatment are based on patients reporting symptoms and clinical observations over months or years. Patients often do not receive timely treatment because the disorder is not correctly recognized. As a result, patients experience multiple hospitalizations and incur socioeconomic disadvantages that can last for decades. Objective biomarkers are important to help implement treatment at an early stage.1

1Cloutier M, et al: J Clin Psychiatry 2016; 77:764–771. Dilsaver SC: J Affect Disord 2011:129:79–83.

Company contact:

Dr. Terry Osborn

Co-founder & CEO

twosborn@lagunadiagnostics.com

 847.778.0522